Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $73,470 - $94,195
-1,244 Reduced 10.9%
10,168 $752,000
Q3 2023

Oct 11, 2023

SELL
$65.94 - $99.04 $94,426 - $141,825
-1,432 Reduced 11.15%
11,412 $778,000
Q2 2023

Jul 10, 2023

BUY
$62.68 - $95.05 $95,649 - $145,046
1,526 Added 13.48%
12,844 $1.21 Million
Q1 2023

Apr 14, 2023

BUY
$47.19 - $70.77 $534,096 - $800,974
11,318 New
11,318 $767,000
Q2 2022

Aug 03, 2022

SELL
$35.61 - $76.23 $174,275 - $373,069
-4,894 Closed
0 $0
Q1 2022

Apr 18, 2022

BUY
$57.56 - $82.54 $27,053 - $38,793
470 Added 10.62%
4,894 $342,000
Q4 2021

Jan 20, 2022

BUY
$72.5 - $100.68 $51,910 - $72,086
716 Added 19.31%
4,424 $344,000
Q3 2021

Nov 01, 2021

BUY
$90.24 - $124.05 $22,469 - $30,888
249 Added 7.2%
3,708 $354,000
Q2 2021

Jul 21, 2021

BUY
$93.66 - $139.27 $36,995 - $55,011
395 Added 12.89%
3,459 $430,000
Q1 2021

Apr 27, 2021

SELL
$116.57 - $155.01 $7,810 - $10,385
-67 Reduced 2.14%
3,064 $404,000
Q4 2020

Feb 01, 2021

SELL
$99.61 - $142.12 $13,148 - $18,759
-132 Reduced 4.05%
3,131 $415,000
Q3 2020

Nov 06, 2020

SELL
$72.92 - $102.01 $11,885 - $16,627
-163 Reduced 4.76%
3,263 $333,000
Q2 2020

Aug 05, 2020

BUY
$55.75 - $92.75 $190,999 - $317,761
3,426 New
3,426 $298,000
Q1 2020

May 07, 2020

SELL
$37.9 - $104.44 $97,440 - $268,515
-2,571 Closed
0 $0
Q4 2019

Jan 15, 2020

SELL
$77.66 - $99.74 $17,939 - $23,039
-231 Reduced 8.24%
2,571 $238,000
Q3 2019

Nov 05, 2019

SELL
$90.37 - $122.49 $352,714 - $478,078
-3,903 Reduced 58.21%
2,802 $253,000
Q2 2019

Jul 22, 2019

BUY
$89.51 - $118.04 $37,952 - $50,048
424 Added 6.75%
6,705 $791,000
Q1 2019

May 14, 2019

BUY
$61.98 - $96.5 $389,296 - $606,116
6,281 New
6,281 $544,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Ae Wealth Management LLC Portfolio

Follow Ae Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ae Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ae Wealth Management LLC with notifications on news.